Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences operating margin
Operating margin is operating income as a percentage of revenue.
Emmaus Life Sciences's operating margin for the twelve months ending Jun 30, 2026 was 29.3%. For fiscal 2025 it was 1.9%, against -11.4% the year before. The highest annual figure on record is 12.0% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.9% | +13.2 |
| FY2024 | Dec 31, 2024 | -11.4% | −23.3 |
| FY2023 | Dec 31, 2023 | 12.0% | +47.8 |
| FY2022 | Dec 31, 2022 | -35.8% | −6.1 |
| FY2021 | Dec 31, 2021 | -29.7% | −29.6 |
| FY2020 | Dec 31, 2020 | -0.1% | +19.7 |
| FY2019 | Dec 31, 2019 | -19.8% | +5508.3 |
| FY2017 | Sep 30, 2017 | -5528.1% | −1101.8 |
| FY2016 | Sep 30, 2016 | -4426.3% | −1779.2 |
| FY2015 | Sep 30, 2015 | -2647.2% | +178.0 |
| FY2014 | Sep 30, 2014 | -2825.2% | +383.8 |
| FY2013 | Sep 30, 2013 | -3209.0% | −2499.6 |
| FY2011 | Sep 30, 2011 | -709.4% | +309.4 |
| FY2010 | Sep 30, 2010 | -1018.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | 60.0% | +76.9 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -41.5% | −56.5 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | 23.0% | +12.2 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | 20.6% | +129.9 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -16.9% | −36.1 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | 15.0% | +14.5 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | 10.8% | −20.1 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -109.3% | −92.1 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | 19.2% | +43.1 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | 0.5% | +13.8 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | 30.9% | +64.5 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -17.3% | +77.6 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -23.9% | +140.5 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -13.4% | −12.8 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -33.6% | −41.0 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -94.9% | −64.6 |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -164.4% | −170.2 |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -0.5% | −0.7 |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | 7.4% | +42.6 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -30.3% | −46.6 |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | 5.8% | +32.4 |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | 0.1% | −2.0 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -35.2% | +7886.9 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | 16.3% | +3863.3 |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -26.7% | +4424.7 |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | 2.1% | +6470.1 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -7922.1% | +910.7 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -3847.0% | −12.0 |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -4451.4% | −1118.1 |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -6468.0% | −3938.9 |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -8832.8% | −6740.2 |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -3835.1% | −2041.5 |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -3333.3% | +399.2 |
| Q1 FY2016CQ4 2015 | Dec 31, 2015 | -2529.1% | +903.4 |
| Q4 FY2015CQ3 2015 | Sep 30, 2015 | -2092.5% | – |
| Q3 FY2015CQ2 2015 | Jun 30, 2015 | -1793.5% | – |
| Q2 FY2015CQ1 2015 | Mar 31, 2015 | -3732.5% | – |
| Q1 FY2015CQ4 2014 | Dec 31, 2014 | -3432.6% | – |
See a number that looks wrong?